CTOs on the Move

Ginkgo Bioworks

www.ginkgobioworks.com

 
At Ginkgo Bioworks we are expanding the role of biology in our world.Nature`s biodiversity holds answers to challenges in health, energy, food, materials, and more. Organism Engineers at Ginkgo learn from Nature to develop new organisms that replace technology with biology.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Michael Kuchinskas
VP of Protein Engineering Profile
Christopher Mellen
Director of Information Security Profile

Funding

Ginkgo Bioworks raised $45M on 07/23/2015
Ginkgo Bioworks raised $100M on 06/08/2016
Ginkgo Bioworks raised $275M on 12/14/2017
Ginkgo Bioworks raised $290M on 09/19/2019

Similar Companies

Fountain Medical Development

FMD K&L is a global contract research organization supporting data management, biostatistics, statistical programming, clinical operations, regulatory affairs, safety, pharmacovigilance, toxicology, medical affairs, medical writing, quality, risk, and compliance services to the pharmaceutical, biotechnology, and medical device industries worldwide. We continuously strive to raise the standard of excellence through accuracy and efficiency to achieve the highest quality output for our partners. K&L was established in the US in 1995, and has grown rapidly worldwide, with key offices and delivery centers in the US, UK, China, India, Armenia, Japan and throughout the Asia-Pacific region.

Lab Co Inc

Lab Co Inc is a Jersey City, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Turner Biosystems

Turner Biosystems is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

QIAGEN

QIAGEN is a German provider of sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research.

Rgenix

Rgenix is a preclinical stage pharmaceutical company with a mission to develop the world`s first cancer therapies designed specifically to target cancer metastasis, the main cause of mortality in cancer patients. Rgenix is leading the revolution in next-generation cancer therapies with first-in-class lead drug candidates for several aggressive cancer subtypes, including Triple-Negative Breast Cancer, Melanoma and Colorectal Cancer.